Skip to main content

Advertisement

Table 2 Drugs for which currently recommended anti-malarial regimens maybe inadequate in important patient groups.

From: Hyperparasitaemia and low dosing are an important source of anti-malarial drug resistance

Drug Dose Patient group Comment
Dihydroartemisinin-piperaquine 2.5/20 mg/kg/day for 3 days All The current adult DHA dose of 120 mg may be too low. The piperaquine dose may be too low in children
Sulphadoxine -pyrimethamine 1.25/25 mg/kg Children, pregnant women Higher doses have not been evaluated
Atovaquone-proguanil 8/20 mg/kg for 3 days Pregnant women Higher doses have not been evaluated
Artemether-lumefantrine 1.5/9 mg/kg for 3 days with fat Pregnant women Hyperparasitaemic patients Lumefantrine absorption is dose limited. Longer courses have not been evaluated in pregnancy
Artesunate Oral 2 mg/kg/day 7 days 2.4 mg/kg i.v. Pregnant women Higher doses have not been evaluated in pregnancy
Artemether Oral 2 mg/kg/day 7 days 3.2 mg/kg i.m. Pregnant women Higher doses have not been evaluated in pregnancy
  1. The efficacy of three day artemisinin-combination regimens in hyperparasitaemia is uncertain. Longer regimens may be necessary